ArticleEndocrine2025
ΔTg assesses radioiodine treatment response and predicts prognosis in pediatric differentiated thyroid cancer with postoperative persistent disease.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study aims to define the relationship between the serum thyroglobulin change rate (ΔTg) after radioactive iodine (RAI) therapy and both RAI therapy response as well as prognosis in pediatric patients with differentiated thyroid cancer (DTC) presenting with postoperative persistent structural disease.
methodsThis retrospective study analyzed 123 RAI courses in 57 pediatric DTC patients with postoperative persistent structural disease. Treatment response was assessed at 6 months post-RAI. Optimal ΔTg thresholds for response classification were determined using ROC analysis with bootstrap validation. The prognostic value of ΔTg for achieving no evidence of disease (NED) and progression-free survival (PFS) was evaluated.
resultsΔTg values differed significantly among response categories (p < 0.001). Median ΔTg values were as follows: Complete Response (CR), 84.5%; Partial Response (PR), 53.8%; Stable Disease (SD), 4.9%; Progressive Disease (PD), -69.0%. ROC analysis identified optimal ΔTg thresholds: ΔTg ≥ 32% for predicting achievement of Objective Response (OR; CR + PR), and ΔTg ≤-14% for predicting PD occurrence. Patients with ΔTg values between − 14% and 32% were classified as having SD. Longitudinally, initial ΔTg ≥ 32% vs. initial ΔTg ≤-14% showed superior PFS (p < 0.001) and higher NED rates. The intermediate group (-14%<ΔTg < 32%) exhibited outcome dissociation: NED rate aligned with ΔTg ≤-14%, while PFS resembled ΔTg ≥ 32%. Multivariable analysis confirmed ΔTg ≤-14% predicted an 11.7-fold higher progression hazard (HR = 11.70, 95%CI:3.27–41.89; p < 0.001).
conclusionsThis study establishes validated ΔTg thresholds for response assessment in pediatric DTC with persistent structural disease (OR: ≥32%; PD: ≤-14%; SD: -14%<ΔTg<32%). Initial ΔTg is a powerful independent prognostic factor. These evidence-based thresholds provide actionable guidance for managing pediatric DTC patients with postoperative persistent disease.
Indexed as
Identifiers
41461947What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.